AN0025

Our Core Product AN0025 is a clinical stage, potential first-in-class EP4 antagonistdesigned to modulate tumor microenvironment. It blocks the PGE2-EP4 signaling pathway to inhibit PGE2-mediated immunosuppression in the tumor microenvironment.


A phase 1b study of AN0025 in combination with the standard of care in a neoadjuvant setting for locally advanced rectal cancer showed excellent results, with nearly 40% of patients not requiring surgery or achieving a complete pathological response in the post-surgical specimen in this study. 


The first patient has been dosed in a phase 1b clinical trial (AN0025S0103) to evaluate AN0025 in combination with KEYTRUDA® (pembrolizumab) in patients with locally advanced/metastatic solid tumors.


 Mechanism of Action
Latest progress
Patients have begun dosing in a phase 1b clinical trial (AN0025S0103) to evaluate AN0025 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with locally advanced/metastatic solid tumors.
Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 at ESMO 2019,with 20% of patients achieving clinical complete remission and 16% achieving pathological complete remission in this study, AN0025 in combination with the standard pre-operative treatment warrants further development.
About Rectal Cancer

Rectal cancer is a disease in which malignant (cancer) cells form in the tissues of the rectum.The global incidences of rectal cancer reached approximately 732,000 in 2020. 


Radiotherapy with or without chemotherapy is the most commonly preoperative treatment for localized advanced rectal cancer to which pCR rates are only around 15%, calling for novel combinations to enhance the efficacy of RT/CRT.